NIKKEI 225
27,781.02+497.43(+1.82%)HANG SENG
26,235.80+274.77(+1.06%)CRUDE OIL
71.44-2.51(-3.39%)GOLD FUTURES
1,816.60-0.60(-0.03%)DOW
34,838.16-97.31(-0.28%)BTC-GBP
28,060.04-1,937.47(-6.46%)
Roche Holding AG (RHHBY)
| Previous close | 48.26 |
| Open | 48.40 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 48.12 - 48.70 |
| 52-week range | 39.72 - 48.79 |
| Volume | 789,008 |
| Avg. volume | 1,191,525 |
| Market cap | 338.006B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 21.62 |
| EPS (TTM) | 2.25 |
| Earnings date | N/A |
| Forward dividend & yield | 1.22 (2.60%) |
| Ex-dividend date | 18 Mar 2021 |
| 1y target est | N/A |
- Globe Newswire
FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Across four phase III studies, approximately half of patients receiving faricimab could extend treatment time to every four months – the first time this level of durability has been achieved in phase III nAMD and DME studiesIf approved, faricimab would be the first and only medicine designed to target two distinct pathways that drive retinal diseases that can cause vision lossThe European Medicines Agency has also validated the faricimab Marketing Authorisation Application submission in nAMD and
- Globe Newswire
Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)
FIREFISH Part 2 study showed treatment with Evrysdi helped babies stay free of permanent ventilation, sit without support and improve across a range of motor milestones Evrysdi has proven efficacy in adults, children and babies two months and older with over 4,000 patients treated to dateSMA is the leading genetic cause of death in infants Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part
- Business Wire
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
SOUTH SAN FRANCISCO, Calif., July 29, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.
